Randomized Phase 2 Study of Neoadjuvant Nivolumab with and without Urelumab in Cisplatin-Ineligible Patients with Muscle-Invasive Urothelial Carcinoma of the Bladder
Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrolling: Male and Female Patients
IRB Number: AAAR7552
U.S. Govt. ID: NCT02845323
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This research is being done to study the effects, safety, and tolerability of the study drugs Nivolumab and Urelumab when given to people with advanced bladder cancer that has spread into the muscle tissue, also called Muscle-Invasive Urothelial Carcinoma of the Bladder (MIBC). Specifically, this research study will have participants either take Nivolumab in combination with Urelumab or Nivolumab alone.
This study is closed
Investigator
Christopher Anderson, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have muscle-invasive urothelial carcinoma of the bladder? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162